about
Harnessing high density lipoproteins to block transforming growth factor beta and to inhibit the growth of liver tumor metastases.Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapyLiver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I.Interferon alpha bioactivity critically depends on Scavenger receptor class B type I function.Scavenger receptor class B, type I: a promising immunotherapy target.Effector CD8+ T cell-derived interleukin-10 enhances acute liver immunopathology.A Semliki forest virus vector engineered to express IFNα induces efficient elimination of established tumors.Characterization of woodchuck apolipoprotein A-I: a new tool for drug delivery and identification of altered isoforms in the woodchuck chronic hepatitis model.Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells.Pathogen-specific B-cell receptors drive chronic lymphocytic leukemia by light-chain-dependent cross-reaction with autoantigens.Immunosurveillance of the liver by intravascular effector CD8(+) T cells.Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein.miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8 T cell fateEradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectinThe transcription factor c-Myb regulates CD8+ T cell stemness and antitumor immunitySingle-cell RNA-seq reveals TOX as a key regulator of CD8+ T cell persistence in chronic infection
P50
Q33567974-034D286E-46BC-484A-8F8F-784CD60C8010Q34533728-86859EE9-2B5F-4673-B4BF-57D380FBBF8CQ35868108-FCA6BAB7-E8BE-42B2-A8B7-2499F9B7D8C6Q37224572-1B94A19A-CE05-4AC5-88CB-D1E9722FFF01Q37851971-1AEDDB72-8082-4F8A-BB36-DA71EE204E08Q38797175-AD63E97A-0DCC-4920-9287-BC378EA05825Q39511476-D9F8570B-56E4-4754-B8BE-F0B0A2C32B0EQ39552882-7CFF12A2-748B-496C-9866-AE01827AC8CDQ39621416-A3C25ACD-6C7F-402A-89BF-66FBC4BCBADAQ40044803-31E4A50C-573B-467D-A288-2DB578C7C514Q41309127-DE2AA70E-59E8-407C-9FED-B9C02C9C3D40Q46748932-B60AFF95-A0A9-4108-85E2-729DCD6860BDQ64056537-917DEB14-C1FA-40B6-849E-9CA71E5156E2Q84904659-3E5092EF-21B2-4189-8D8F-C76CD1142E95Q91692140-C7D1B259-5EDC-45C0-9BBA-63716B4ACB55Q92826927-3CFACED8-FA6E-46E6-B1C0-6A73DBFB3943
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jessica Fioravanti
@ast
Jessica Fioravanti
@en
Jessica Fioravanti
@es
Jessica Fioravanti
@nl
type
label
Jessica Fioravanti
@ast
Jessica Fioravanti
@en
Jessica Fioravanti
@es
Jessica Fioravanti
@nl
prefLabel
Jessica Fioravanti
@ast
Jessica Fioravanti
@en
Jessica Fioravanti
@es
Jessica Fioravanti
@nl
P108
P106
P108
P1153
36987364400
P21
P31
P4012
P496
0000-0001-6263-4306